Increased m-calpain expression in the mesencephalon of patients with parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?

[1]  M. Fujiwara,et al.  Calpain is implicated in rat myocardial injury after ischemia or reperfusion. , 1994, Japanese circulation journal.

[2]  E. Hirsch,et al.  Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease? , 1994, Brain Research.

[3]  T B Shea,et al.  Calcium‐Activated Neutral Proteinase (Calpain) System in Aging and Alzheimer's Disease a , 1994, Annals of the New York Academy of Sciences.

[4]  R. Siman,et al.  Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[5]  E. Hirsch,et al.  Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease , 1994, Neuroscience Letters.

[6]  P. Andiné,et al.  Upregulation of calpain activity in neonatal rat brain after hypoxic-ischemia , 1993, Brain Research.

[7]  B. Vandenbunder,et al.  High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro , 1993, Cell.

[8]  J. Karlsson,et al.  Immunohistochemical localization of calpains and calpastatin in the rabbit eye , 1993, Brain Research.

[9]  J. Krieglstein,et al.  Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo , 1993, Brain Research.

[10]  R. Nixon,et al.  Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  E. Hirsch,et al.  Glutathione peroxidase, glial cells and Parkinson's disease , 1993, Neuroscience.

[12]  C. W. Olanow,et al.  Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study , 1992, Brain Research.

[13]  K. Jellinger,et al.  Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis , 1992, Journal of neurochemistry.

[14]  Irene Litvan,et al.  Progressive supranuclear palsy : clinical and research approaches , 1992 .

[15]  E. Hirsch.  Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? , 1992, Annals of neurology.

[16]  P. Emson,et al.  Localization of calpain immunoreactivity in senile plaques and in neurones undergoing neurofibrillary degeneration in Alzheimer's disease , 1991, Brain Research.

[17]  G. Lynch,et al.  Inhibition of proteolysis protects hippocampal neurons from ischemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Karlsson,et al.  Changes in brain calpain activity as a result of in vitro ischemia and pH alterations. , 1991, Molecular and chemical neuropathology.

[19]  Y. Agid,et al.  Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.

[20]  M. Mattson,et al.  Evidence for calcium-reducing and excitoprotective roles for the calcium-binding protein calbindin-1328k in cultured hippocampal neurons , 1991, Neuron.

[21]  C. Heizmann.  Novel Calcium-Binding Proteins , 1991, Springer Berlin Heidelberg.

[22]  T. Fukuda,et al.  Immunohistochemical distribution of calcium‐activated neutral proteinases and endogenous CANP inhibitor in the rabbit hippocampus , 1990, The Journal of comparative neurology.

[23]  K. Blomgren,et al.  Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue , 1990, Neurobiology of Aging.

[24]  E. Hirsch,et al.  Tyrosine hydroxylase-like immunoreactivity in senile plaques is not related to the density of tyrosine hydroxylase-positive fibers in patients with Alzheimer's disease , 1990, Neuroscience Letters.

[25]  K. Suzuki,et al.  Calcium activated neutral protease--structure-function relationship and functional implications. , 1990, Cell structure and function.

[26]  P. Riederer,et al.  The role of monoamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson's disease. , 1990, Journal of neural transmission. Supplementum.

[27]  E. Hirsch,et al.  Choline acetyltransferase-like immunoreactivity in the hippocampal formation of control subjects and patients with Alzheimer's disease , 1989, Neuroscience.

[28]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[29]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[30]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[31]  K. Blomgren,et al.  Calpain and calpastatin levels in different organs of the rabbit. , 1989, Comparative biochemistry and physiology. B, Comparative biochemistry.

[32]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[33]  K. Imahori,et al.  Tissue distribution of calcium-activated neutral proteinases in rat. , 1988, Biochimica et biophysica acta.

[34]  G. Lynch,et al.  The ultrastructural localization of calcium‐activated protease “calpain” in rat brain , 1988, Synapse.

[35]  Forno Ls,et al.  The Lewy body in Parkinson's disease. , 1987 .

[36]  A. Matus,et al.  Distribution of calpains I and II in rat brain , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[37]  J. Karlsson,et al.  Characterization of Brain Calpains , 1986, Journal of neurochemistry.

[38]  R. Nixon,et al.  Multiple calcium-activated neutral proteinases (CANP) in mouse retinal ganglion cell neurons: specificities for endogenous neuronal substrates and comparison to purified brain CANP , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[39]  A. Ciechanover,et al.  The ubiquitin pathway for the degradation of intracellular proteins. , 1986, Progress in nucleic acid research and molecular biology.

[40]  G. Lynch,et al.  Distribution of calpain I, an enzyme associated with degenerative activity, in rat brain , 1985, Brain Research.

[41]  G. Lynch,et al.  Regional distribution of soluble calcium activated proteinase activity in neonatal and adult rat brain , 1985, Brain Research.

[42]  Y Agid,et al.  [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. , 1984, European journal of pharmacology.

[43]  D. Lehotay,et al.  Characterization of a calcium-activated protease that hydrolyzes a microtubule-associated protein. , 1981, Archives of biochemistry and biophysics.

[44]  H. Gainer,et al.  Properties of a calcium-activated protease in squid axoplasm which selectively degrades neurofilament proteins. , 1980, Journal of neurobiology.

[45]  E. Weibel.  Stereological Methods. Practical methods for biological morphometry , 1979 .

[46]  K. Earle.  Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. , 1968, Journal of neuropathology and experimental neurology.